|
|
Abstract
FTC in an outpatient group: switch of a stable virus-controlled ART to a FTC-containing regimen
Fenske S.1
Background: Good adherence over a long period of time is one of the most important goals to prevent development of resistance. A regimen with less side effects and an easy to take-regimen (e.g. number of pills/day, qd or bid regimens) might be important parts to reach a high grade of adherence. FTC is a synthetic nucleoside analogue with a standard dose of one capsule of 200 mg qd, which was developed for qd dosage from the beginning. FTC in combination with ddI is superior to an d4T/ddI containing regimen (FTC 301/301A). In a study with therapy naïve patients (FTC 302) and in patients receiving a 3TC-containing regimen with viral-load < 400/<50 copies (FTC 303) there is no significant difference between the FTC and the 3TC-containing treatment-arms. FTC has shown high potency, a low grade of toxicity and is usually well tolerated. The long intracellular halflife of the triphosphate FTC might increase the robustness of HAART, especially of complete qd regimens.
Objectives: To assess whether a switch to an FTC-containing HAART in patients with undetectable viral load is safe and effective. Results 51 patients on a stable ART with viral-load less than 25 copies/ml where switched to a FTC-containing regimen. 44/51 where switched from 3TC to FTC, 2/51 from ddI/d4T to FTC/ddI (1) or FTC/TDF (1); 1/51 from AZT/ddI to FTC/TDF, 1/51 from ddI/ABC to FTC/ABC and 1/51 from ABC/d4T/ddI to FTC/TDF. 49/51 patients receiving a FTC/TDF backbone after switching therapy. 32/51 patients are on a boosted PI, 19/32 on a NNRTI-containing combination therapy. During the observation-period from 2-15 months (median 7,02 months) on the FTC-containing regimen no discontinuation or switch of FTC was needed due to viral failures or side-effects.
Conclusions: FTC as part of a combination therapy is a well tolerated and safe drug. There are no virological failures during the obervation period
The 3rd IAS Conference on HIV Pathogenesis and Treatment
Abstract no.
WePe12.3C01
Suggested Citation
" Fenske S.
FTC in an outpatient group: switch of a stable virus-controlled ART to a FTC-containing regimen.
Poster Exhibition:
The 3rd IAS Conference on HIV Pathogenesis and Treatment:
Abstract no.
WePe12.3C01"
|
|
|